Bi-Est Cream Dosing (80/20)
There is no FDA-approved or guideline-supported dosing regimen for compounded Bi-Est cream (80% estriol/20% estradiol), and the available evidence shows these compounded preparations deliver significantly lower and unpredictable estrogen levels compared to FDA-approved products—therefore, I recommend using FDA-approved low-dose vaginal estradiol products instead (10 µg tablets twice weekly or 0.3 mg conjugated estrogen cream) for vaginal symptoms, or FDA-approved transdermal estradiol patches (0.025-0.05 mg) for systemic symptoms. 1, 2
Why Bi-Est Cream Is Problematic
The "80/20" formulation you're asking about refers to compounded bioidentical hormone preparations, but this creates several critical issues:
Lack of standardization: Compounded Bi-Est creams have no FDA approval, no standardized dosing guidelines, and no quality control requirements 3, 4
Significantly lower estrogen delivery: Research demonstrates that compounded transdermal estradiol creams deliver substantially lower estrogen levels than FDA-approved patches and gels at comparable doses. Even at doses of 1.5-3.0 mg, compounded creams produced urinary estradiol levels significantly lower than FDA-approved products 4
Unpredictable pharmacokinetics: A randomized trial testing Bi-Est cream at 2.0,2.5, and 3.0 mg doses found consistently lower estrogen levels (AUC-estradiol of 181-286) compared to standard 0.05 mg estradiol patches (AUC-estradiol of 917-956), with statistical significance at p<0.001 3
Evidence-Based Alternatives
For Vaginal Symptoms (Genitourinary Syndrome of Menopause)
Low-dose vaginal estradiol is the gold standard 1:
10 µg estradiol vaginal tablets: Daily for 2 weeks, then twice weekly maintenance. Relieves symptoms by 8 weeks and remains effective for at least 52 weeks 1
Vaginal estradiol cream (FDA-approved): 2-4 g daily for 1-2 weeks, then 1 g maintenance 1-3 times weekly 2
Low-dose vaginal ring: Changed every 3 months, maintains postmenopausal estradiol levels 1
For Systemic Menopausal Symptoms
FDA-approved transdermal estradiol patches or gels provide predictable, consistent hormone delivery 4:
- Start with lowest effective dose (typically 0.025-0.05 mg patches)
- Titrate based on symptom response
- Add progestin if uterus is intact to prevent endometrial hyperplasia 2
Critical Safety Considerations
If a woman has an intact uterus, unopposed estrogen increases endometrial cancer risk 2. The Bi-Est formulation you mentioned includes progesterone, but:
- Compounded progesterone absorption and endometrial protection are not well-studied in the cream formulation
- FDA-approved oral micronized progesterone (100-200 mg) or progestin therapy provides proven endometrial protection 2, 5
Common Pitfalls to Avoid
Don't assume "bioidentical" means safer: This is marketing terminology without regulatory meaning 3
Don't rely on serum estradiol monitoring with compounded creams: The pharmacokinetics are too unpredictable to guide dosing effectively 3, 4
Don't use compounded products when FDA-approved alternatives exist: Professional societies including the Endocrine Society recommend FDA-approved products due to quality control and proven efficacy 1
Use lowest effective dose for shortest duration: This applies to all estrogen therapy regardless of formulation 1, 2
Practical Algorithm
If patient specifically requests compounded Bi-Est despite counseling:
- Acknowledge that no evidence-based dosing exists
- Typical compounding pharmacy doses range 1.25-5 mg total estrogens per gram, but these deliver unpredictably low systemic levels 3, 4
- Monitor clinically for symptom relief rather than serum levels
- Ensure adequate progestin coverage if uterus intact (oral micronized progesterone 100-200 mg daily is better studied than compounded progesterone cream)
- Strongly consider transitioning to FDA-approved products for predictable efficacy and safety profile